Company intelligence / Profile preview
TerSera Therapeutics
Deerfield, Illinois, USAtersera.com ↗
- Ownership
- Private
- Employees
- ~165
- Development stage
- Other
01
Overview
TerSera Therapeutics commercializes and develops specialty pharmaceuticals focused on oncology, acute care, non-opioid pain management, and rare diseases. Its portfolio includes several FDA-approved drugs such as Zoladex® for hormone-sensitive cancers, Xermelo® for carcinoid syndrome diarrhea, Quzyttir™ injection to prevent infusion reactions, and the soon-to-be-acquired MARGENZA® monoclonal antibody for metastatic HER2+ breast cancer.
- Therapeutic areas
- GastroenterologyOncologyNeurology
- Modalities
- Small moleculesSynthetic peptidesMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
AstraZeneca—for US & Canada rights to Zoladex®MacroGenics—for global rights to MARGENZA® monoclonal antibody therapy
Beyond the preview
Go deeper on TerSera Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TerSera Therapeutics.